NAD+ (and precursors NMN / NR)

Summary

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, essential for energy metabolism, DNA repair, and the activity of enzymes (sirtuins, PARPs) linked to aging. You can't usefully "take NAD+" as a pill — the molecule is too large to absorb intact — so products instead supply precursors the body converts to NAD+, mainly NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside), or deliver NAD+ by IV drip. The honest state of the evidence: these supplements do reliably raise NAD+ levels in the blood, but human trials have so far mostly failed to show the metabolic, muscle, and anti-aging benefits the marketing promises. There is a real gap between "moves a biomarker" and "makes you healthier."

What people use it for

NAD+ and its precursors are marketed and used for anti-aging and longevity, more energy, better metabolism (blood sugar, weight, cholesterol), improved muscle and exercise performance, cognitive sharpness, and recovery. IV NAD+ drips are sold by wellness clinics for "cellular energy," hangover/addiction recovery, and general rejuvenation. These are the claims the evidence sections test; describing them is not endorsement.

Human evidence

The strongest, most consistent human finding is narrow: oral NMN and NR raise NAD+ levels in the blood in a dose-dependent way. For example, controlled trials of NR have shown blood NAD+ rising substantially with daily dosing. That part is well established.

The problem is what happens downstream. Multiple independent systematic reviews and meta-analyses of randomized controlled trials have looked for actual health benefits and largely come up empty:

• For metabolic health, a 2024 meta-analysis of 12 NMN RCTs (about 513 participants) found NMN significantly raised blood NAD+ but that most clinically relevant outcomes did not differ from placebo. A separate meta-analysis of 8 NMN RCTs (about 342 adults) found no significant benefit on fasting glucose, fasting insulin, HbA1c, insulin resistance (HOMA-IR), or lipid profile.
• For muscle and physical performance in older adults, a systematic review/meta-analysis of NMN and NR RCTs concluded the supplements offer minimal benefit for sarcopenia, muscle strength, or physical performance, and another trial in chronic-kidney-disease patients found NR did not improve exercise capacity (VO₂peak) versus placebo. Some individual trials report small effects (e.g., a 2024 trial reported modestly faster walking speed and better self-reported sleep at 250 mg/day), but these are not consistent across the literature.

So the fair summary is: NAD+ precursors do what they say at the biochemical level (raise NAD+) and appear safe in trials up to ~26 weeks, but the human evidence does not yet support the headline claims of better metabolism, more strength, or slower aging.

A special note on IV NAD+, which drip clinics promote heavily: there is very little controlled efficacy data for it, and a 2019 pilot study that infused NAD+ intravenously over 6 hours found — surprisingly — no measurable rise in plasma NAD+ during the infusion itself (the body appears to rapidly metabolize it), raising basic questions about what IV NAD+ is actually delivering to cells.

Animal / preclinical evidence

The enthusiasm for NAD+ comes largely from animal work, where it looks far more impressive than in people. In mice, boosting NAD+ (often with NMN) has been reported to improve insulin sensitivity, reduce age-associated weight gain, enhance energy metabolism and physical activity, protect the heart from ischemia, partially restore aged skeletal muscle, and slow cognitive decline in Alzheimer's models. This large and consistent rodent literature is what drives the supplement industry and the "fountain of youth" framing.

Two cautions. First, the mouse-to-human translation has repeatedly underdelivered: as the human RCT section shows, the dramatic metabolic effects in mice have not reproduced in people so far. Second, the foundational premise — that NAD+ universally declines with age and that restoring it reverses aging — is itself contested: a 2022 review specifically examining the evidence concluded that, despite confident claims, the data showing an overall age-related NAD+ decline (especially in humans) is actually quite limited and inconsistent across tissues and species.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

Users of NAD+ precursors and IV drips commonly report more energy, mental clarity, and a general sense of well-being. These reports are sincere but are exactly what a biomarker that rises without consistent clinical benefit, combined with expectation and the placebo effect, would produce — which is why controlled trials matter. The subjective "energy boost" from an IV NAD+ drip in particular has no strong controlled evidence behind it.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

In published human trials, oral NMN was typically studied at roughly 250–2000 mg/day for 2–12 weeks, and NR trials have used doses up to ~1000–2000 mg/day, with blood NAD+ rising in a dose-dependent way (e.g., NR producing increases of roughly 22%, 51%, and 142% at 100, 300, and 1000 mg). IV NAD+ pilot work used slow infusions over several hours. These figures describe what was administered in studies and are reported for context only — not as a protocol — especially since raising NAD+ has not reliably translated into health benefits.

Safety & side effects

In clinical trials, NAD+ precursors have generally been well tolerated, with more than a dozen trials (up to 26 weeks, one lasting two years) reporting good short-term safety and mostly mild side effects. That said, long-term safety in healthy people taking these for years is not established, and there are open theoretical questions — including whether chronically boosting NAD+ could affect cancer biology, since NAD+ metabolism is also exploited by tumors (an area of active, unsettled research). IV NAD+ infusions can cause uncomfortable acute effects (chest tightness, nausea, flushing) if run too fast, and carry the general risks of any IV procedure. Product quality is a practical concern: independent testing has found NAD-related supplements vary, and NMN's regulatory limbo (below) means oversight is inconsistent.

Regulatory / legal status

NAD+ itself and NR are generally sold in the U.S. as dietary supplements, not as approved drugs. NMN's status is contested: the FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was authorized for investigation as a drug, which has created marketplace uncertainty about whether NMN can lawfully be sold as a supplement. IV NAD+ is offered by wellness and "drip" clinics but is not an FDA-approved therapy for any condition. Critically, none of these — oral or IV — is FDA-approved to treat, prevent, or reverse aging or any disease, and marketing that claims so is making unproven medical claims. Status can change and varies by jurisdiction; this is not legal or medical advice.

Podcast / media mentions

NAD+ is one of the most heavily promoted molecules in the longevity space, amplified by high-profile researchers (e.g., David Sinclair's work on NAD+, sirtuins, and resveratrol) and a large supplement industry. Much of the public-facing material presents the mouse results and the "NAD+ halves by middle age, so restore it" story as settled fact — including review articles authored by supplement-company founders, which should be read as marketing-adjacent rather than independent science. The accurate version is more modest: the biology is real and genuinely interesting, NAD+ precursors do raise NAD+, the safety looks reasonable short-term — but the human outcome data has so far not delivered the anti-aging, metabolic, or performance benefits the loudest promotion implies. The critique here is of the certainty and the commercial framing, not of studying NAD+ biology, which is a legitimate and active field.